Studies of the mechanism of the anticonvulsant effect of delta-sleep-inducing peptide in conditions of increased oxygen tension

• Published in: Neuroscience and behavioral physiology Vol. 27; no. 6; pp. 714 - 717
• Main Authors: Mendzheritskii, A M, Lysenko, A V, Uskova, N I, Sametskii, E A
• Format: Journal Article
• Language: English
• Published: United States 01-11-1997
• Subjects: Animals; Anticonvulsants - pharmacology; Atmosphere Exposure Chambers; Cerebral Cortex - drug effects; Cerebral Cortex - metabolism; Cerebral Cortex - physiopathology; Delta Sleep-Inducing Peptide - pharmacology; Electroencephalography; Hyperbaric Oxygenation - adverse effects; Male; Neurotransmitter Agents - metabolism; Rats; Seizures - etiology; Seizures - metabolism; Seizures - prevention & control; Sleep - drug effects; Space life sciences; Wakefulness - drug effects
• ISSN: 0097-0549; 1573-899X
• DOI: 10.1007/BF02461934

Studies of the protective actions of three doses of delta-sleep-inducing peptide (DSIP) given at different times before barochamber compression of animals to an oxygen tension of 0.7 MPa showed that the optimum DSIP dose is 12 micrograms/100 g. Intraperitoneal administration of this dose of DSIP delayed the onset of generalized convulsive activity by a factor of 2-2.5 in animals exposed to an oxygen tension of 0.7 MPa and promoted normalization of the sleep-walking cycle within 24 h after exposure to hyperbaric oxygen (HBO), by creating an optimal balance between excitatory and inhibitory amino acid neuromediators.